AGE (短名 ),
Human AGE/ Advanced glycation end-product CLIA Kit
Natural and recombinant human Advanced glycation end-product
Serum, plasma, tissue homogenates, cell culture supernates and other biological fluids
An advanced glycation end-product (AGE) is the result of a chain of chemical reactions after an initial glycation reaction. The intermediate products are known, variously, as Amadori, Schiff base and Maillard products, named after the researchers who first described them. (The literature is inconsistent in applying these terms. For example, Maillard reaction products are sometimes considered intermediates and sometimes end products.) Side products generated in intermediate steps may be oxidizing agents (such as hydrogen peroxide), or not (such as beta amyloid proteins). "Glycosylation" is sometimes used for "glycation" in the literature, usually as 'non-enzymatic glycosylation.'
"Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes"
M Kopytek, M Ząbczyk, P Mazur, et al.
"Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 ..."
A Aleksandra, N Dariusz, Z Dorota, et al.
From: Microvascular Research
"The C-terminal tails of 4,4'-diphenylmethane-bis(methyl) carbamate are essential for binding to receptor for advanced glycation end products to attenuate advanced glycation end products-induced inflammation and apoptosis responses in human umbilical vein endothelial cells "
Feng L, Zhu M, Bu W, et al.
"c-reactive protein, advanced glycation end products, and their receptor in type 2 diabetic, elderly patients with mild cognitive impairment"
Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, et al
评论数 : 0
规格 数量 价格 ($) 小计 1 ($)
小计 2: $
规格 数量 价格 ($)